Weekly Update | Pharmatell

Eyes on Pharma

Check-out What Intel Caught our Eye

Oct 56 min

Eyes on BMS, Pfizer, & Amgen

Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...

Sep 205 min

Eyes on BioPharma Headlines

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait

Mar 244 min

Eyes on Current Events - Deals, Approvals & Operations

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.

Dec 1, 20233 min

Eyes on Clinical Trial Data, Supply Upgrades, and Patent Litigation

The news this week was full of "Ups-n-Downs." We've noted a few here and know there were more surprises with clinical data results, M&A, and

Apr 4, 20222 min

PharmaTell Studio Upgrades

We are excited to share the latest upgrades to PharmaTell Studio making it even easier for you to keep your eyes on you & your competition.

Mar 20, 20222 min

Gene Therapy Guidance

This week, the team had Eyes on the new draft guidance from the US FDA on Gene Therapy Products Incorporating Genome Editing.

Mar 13, 20221 min

Industry Intel

Today we’ll share some of the types of reports available that can help you keep your Eyes on Pharma Sectors.

Mar 6, 20222 min

Tracking Data

We found several different types of intel so we thought we would share some with you – and tips on how to find it.

Feb 27, 20222 min

Opioids, SPACs, Top 10 Lists, and more Results

Check out the latest on some of the Opioid Litigation, SPACS, and yes two Top 10 Lists!

Feb 22, 20222 min

R&D Trends, ASCO-GU, & Earnings

The Eyes on Pharma team was caught up in reviewing global R&D trends and following the updates from ASCO-GU ...